Teva Pharmaceutical has licensed rights to commercialize glatiramer acetate to Takeda Pharmaceutical in Japan as part of their agreement signed earlier in 2013.
Currently both the firms are working on additional agreements for implementation of the license.
Developed by Teva, glatiramer acetate for injection is indicated for the relapse prevention of multiple sclerosis and is marketed under the brand name Copaxone.
The drug is considered standard treatment for relapsing-remitting multiple sclerosis including patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.
It is currently approved in 55 countries worldwide, including the US, Russia, Canada, Mexico, Australia, Israel, and all European countries.
Under the deal, Teva will grant Takeda commercialization rights in Japan, and Takeda will submit a New Drug Application (NDA) for registration of glatiramer acetate in Japan.
Both the firms will work together to provide a new treatment options to patients with multiple sclerosis in Japan as early as possible, where the current available therapies are still limited.
